Kayne Anderson Rudnick Investment Management
JANX icon

Kayne Anderson Rudnick Investment Management’s Janux Therapeutics JANX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42
Closed -$1K – 645
2022
Q1 		$1K Buy
+42
New +$687 ﹤0.01% 634

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's JANX Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Janux Therapeutics (JANX) in Q2 2022, closing a stake of 42 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in JANX in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 44 funds tracked by Wall St. Rank hold JANX as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Janux Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 42 Janux Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Janux Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Janux Therapeutics position peaked at $1K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.